svmpharma real world evidence - rwe in submissions to nice grew 6% in 2016. rwe has found it’s...
TRANSCRIPT
RWE in submissions to NICE grow 6% in 2016RWE has found it’s place, but what next?
SVMPharma RWE projects are built on the strengths of:• Knowing the RWE landscape• Establishing connections with
healthcare professionals and key opinion leaders
• Intelligent use of technology
RWE in submissions to NICE grew 6% in 2016RWE has found it’s place, but what next?
For more on RWE visit: www.svmpharma.com
1. Key to Market Access: Making the most out of Real World Evidence
2. NICE and the NHS are changing the way they look at cost-effective and innovative drugs in the UK
3. Speeding up approval with RWE: Accelerated Approval and Access programs
RWE messages that you may have missed out on(Click on the links below to find out more)
RWE: the emerging landscapeSVMPharma RWE is built on thestrength of understanding the RWElandscape.
In 2016, of 56 NICE publishedtechnology assessments, around42% utilized some form of RWE, upfrom 36% in 2015. This growthdemonstrates how RWE looks set tocontinue expanding throughout2017.
However, it isn’t just the number ofRWE studies and NICE submissionsthat indicates growth in RWE; newinitiatives illustrate how RWE hasbecome ‘part of the mindset’ inR&D and healthcare economicsover recent years.
As well as supporting HTAsubmissions, RWE is increasinglydriving faster access to drugs:
• The 2016 reforms to cancer drugsfund highlight growingopportunities for RWE.
• January 2017 saw NICE announceinvolvement in ROADMAP, an EUproject in accordance with theInnovative Medicines Initiative(IMI) to share RWE indevelopment of AD drugs.
• With the end of EMA’s pilot inAugust 2016, saw the final reportconclude “the benefit of adaptivepathways lies…in exploring the fullpotential of utilising the realworld evidence generated inclinical practice to refineregulators’ and otherstakeholders’ decisions.”
The increase in RWE studies over the last year and the growth andintroduction of initiatives around RWE highlight how it’s not just becomingcommonly used to support HTA, but already entering wider researchprocesses. In turn, this will improve RWE discussion, standards and uptakewhich makes the coming years an exciting time for RWE.
RWE in submissions to NICE grew 6% in 2016RWE has found it’s place, but what next?
CONTACT SVMPHARMA
Vaneet NayarDirector SVMPharma
Tel: +44 (0) 1252 417030
SVMPharma Ltd
Visit svmpharma.com
Follow @svmpharma
Follow on Google+
Connect via LinkedIn
Get In Touch